American Well Corporation (AMWL) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary shows mixed signals. Financial performance and guidance are not particularly strong, with some revenue decline and negative EBITDA guidance, but there is optimism in strategic initiatives and partnerships. The Q&A reveals management confidence in overcoming challenges and achieving breakeven by 2026. However, the lack of specific KPIs and unclear management responses could raise investor concerns, balancing out potential positives. Therefore, the stock price reaction over the next two weeks is likely to be neutral.
Key Financial Performance
Total Revenue $70.9 million for Q2 2025, which is 13% higher than Q2 2024. Normalizing for the sale of Amwell Psychiatric Care (APC), Q2 revenue was 25% higher than a year ago. The increase is attributed to strategic client deployments and meeting important milestones.
Subscription Software Revenue $40.4 million for Q2 2025, up 47% from a year ago and compared to $32.2 million from Q1 2025. The growth was driven by a material uplift in subscription software revenue related to deploying solutions across the Military Health System.
Visits Completed Approximately 1.2 million visits in Q2 2025, which is approximately 22.3% lower than a year ago. The decline was in line with expectations and reflects a shift in focus towards virtual primary care and specialty programs.
Average Revenue Per Visit $73 in Q2 2025, which is 9% lower compared to Q2 2024. However, after normalizing for the APC sale, it was 8.3% higher than last year, driven by a mix shift towards virtual primary care and specialty programs.
Gross Margin 56.1% for Q2 2025, higher by 3.3 percentage points compared to Q1 2025. The improvement reflects a higher software mix and benefits from ongoing cost initiatives.
Adjusted EBITDA Negative $4.7 million for Q2 2025, compared to negative $35 million in Q2 2024. The improvement is attributed to cost reduction initiatives and a shift towards a higher mix of subscription software revenues.
Cash Burn Reduced to $3 million in Q2 2025, ending the quarter with $219 million in cash and marketable securities, with zero debt. The reduction reflects improved financial management and cost-saving measures.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Amwell Navigate: A new digital-first customer experience designed to empower clients and enable cost-effective quality support at scale.
Military Health System (MHS) Expansion: Amwell's SaaS platform now powers MHS provider video visits, with virtual visits nearly tripling since implementation. Expansion includes U.S. Coast Guard and Military Entry Processing Command (MEPCOM).
Florida Blue Partnership: Amwell was selected by Blue Cross Blue Shield of Florida to provide a white-labeled platform for integrated clinical programs.
Cost Initiatives: Streamlined teams and implemented AI to improve efficiency, resulting in better-than-expected quarterly EBITDA improvements.
Revenue Mix Transformation: Increased subscription software revenue to 57% of total revenue, up 47% year-over-year.
Focus on AI: Amwell is leveraging AI to enhance clinical decision-making, data analytics, and operational efficiency.
Government Sector Expansion: Strategic focus on expanding role in healthcare modernization within the federal market.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Budget restrictions in the Department of Defense: The 2026 contract extension excluded behavioral health and automated care programs due to budget restrictions, impacting revenue and growth opportunities in this segment.
Decline in visit metrics: Visits completed in Q2 were approximately 22.3% lower than the previous year, which could indicate challenges in maintaining user engagement or demand for services.
Revenue dependency on non-recurring contracts: A significant portion of subscription software revenue growth was non-recurring, tied to specific go-lives and contract timing, which may not sustain future revenue growth.
Pressure on average revenue per visit: Average revenue per visit decreased by 9% compared to the previous year, reflecting potential pricing pressures or shifts in service mix.
Challenges in healthcare technology adoption: Healthcare organizations face challenges such as consumer engagement, data fragmentation, regulatory compliance, and integrating clinical programs into whole-person care models, which could impact Amwell's ability to scale effectively.
High customer acquisition costs for clinical program vendors: Vendors face rising costs to acquire customers and pressure to integrate solutions, which could strain Amwell's resources and profitability.
Economic uncertainties and budget constraints: Broad budget restrictions, particularly in government contracts, could limit growth opportunities and revenue stability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2025: Revised revenue guidance for 2025 is in the range of $245 million to $250 million, down from the prior range of $250 million to $260 million.
Subscription Software Revenue: Expected to represent 53% of total 2025 revenues, compared to slightly over 45% in 2024.
Adjusted EBITDA Guidance for 2025: Narrowed to a range of negative $50 million to negative $45 million, demonstrating a 65% improvement year-over-year.
Q3 2025 Revenue Guidance: Expected revenue for Q3 2025 is in the range of $53 million to $56 million.
Q3 2025 Adjusted EBITDA Guidance: Expected to be in the range of negative $15 million to negative $13 million.
Cash Flow Projections: The company is on track to achieve positive cash flow from operations during 2026 and anticipates ending 2025 with approximately $190 million in cash.
Cost Reduction Initiatives: R&D expenses are expected to decline by more than 10% in 2025 compared to 2024. Sales and marketing costs are expected to decline over 25%, and G&A expenses are expected to reduce by more than 20% year-over-year.
Market Trends and Strategic Focus: The company anticipates a significant shift from brick-and-mortar to technology-enabled care, with AI playing a central role in improving efficiency, clinical decision-making, and data analytics.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How does the revenue run rate of the extended DHA contract compare to the pilot contract?
A:The annualized value of the extended DHA contract for subscription revenue is slightly greater than the prior billings, with a small increase provided by the government.
Q:Are there any KPIs that the government will rely upon to decide whether to renew the DHA contract into 2027?
A:Management did not specify exact KPIs but emphasized the platform's past success, including tripling the traction of the previous system, and expressed confidence in continuing to deliver strong performance.
Q:Does the expected subscription revenue for 2025 indicate a decline of $22 million to $30 million, and what is driving this decrease?
A:Management clarified that the expected decrease is due to the extension of go-live times for automated care and behavioral health, which were included in projections for five months of 2025. This adjustment narrowed the guidance range.
Q:How does the company plan to achieve its cash flow from operations breakeven target for 2026?
A:The company plans to achieve this target through product focus, divesting older solutions, focusing on modern platforms, targeting high-margin market segments, reducing operational costs, embracing AI, and transitioning to a centralized configured platform.
Q:What is the management's view on the decision to exclude behavioral and automated care from the DHA contract?
A:Management believes the exclusion is due to broad budget reasons rather than performance issues. They expect these programs to be added later as they generate savings and improve access and care.
Q:Does the guidance change at the EBITDA line reflect only the MHS scale change?
A:Yes, the guidance change at the EBITDA line reflects the impact of the government contract delay and the positive impact of cost reductions made earlier in June.
Q:Did the divestiture have any impact on prior guidance at the revenue or EBITDA line?
A:No, the divestiture did not impact prior guidance at the revenue or EBITDA line.
Q:Are recent macro developments and regulations impacting the sales pipeline?
A:Management noted strong demand and highlighted the market's focus on cost savings. They believe their platform's efficiency and AI capabilities are advantageous in the current environment.
Q:How should R&D expenses be expected to change into next year, and does the DHA contract extension affect R&D plans?
A:R&D expenses are expected to decrease by at least 10% year-over-year in 2025 compared to 2024. The DHA contract extension does not change existing R&D plans.
Q:If the DHA wanted to reinclude automated care and/or behavioral health in a future extension, would it be relatively turnkey?
A:Yes, adding these programs would be relatively turnkey as they are already deployed, certified, and generating results. The platform is designed to easily add clinical programs.
Q:What is the management's outlook on the government pipeline and the DHA extension's role in penetrating the market?
A:Management is optimistic about the government pipeline and views the DHA extension as strong validation of their capabilities, which could lead to opportunities in similar environments.
Q:Do third-party clinical solutions contribute to gross margins, and what is the value proposition of accessing these through Amwell?
A:Yes, third-party solutions contribute to high-margin revenue. Amwell's platform integrates these solutions, providing a seamless experience, reducing customer acquisition costs, and enabling holistic care and reporting.
Q:Have macro factors led to sales cycle elongation or pricing changes?
A:Management has not observed significant elongation in sales cycles. The market's focus on cost savings aligns with Amwell's value proposition, potentially accelerating decision-making.
Q:Why was the DHA contract renewal only for one year, and is this typical?
A:The one-year renewal was influenced by broad budget considerations and new administration negotiations. Multiyear agreements are typical, and management believes this does not reflect negatively on their value or partnership.
Q:What are the expectations for gross margins in the second half of the year and beyond?
A:Gross margins are expected to remain consistent with initial guidance. The second quarter's margins were positively impacted by implementation work and software revenue, but margins will likely be flattish for the remainder of the year.
Q:Review of Unclear Management Responses
A:Management avoided providing specific KPIs for the DHA contract renewal decision and did not disclose a dollar amount for the revenue run rate comparison between the extended and pilot contracts. Additionally, they used broad language to explain the exclusion of behavioral and automated care from the DHA contract, attributing it to budget reasons without detailed evidence.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
APC
Florida
Hirschhorn
LLC Research
MHS provider
Military Health
RD
Research Division
SaaS software
System
adoption
benefit
challenge
commitment
cost path
decision making
engagement SaaS
extension engagement
front
goal cash
healthcare client
healthcare organization
highlight
improvement
intelligence catalyst
marketing GA
mix
platform Military
software platform
software revenue
team
tech care
technology care
tonight
AMWL Transcript
American Well Corporation (AMWL) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call lacked detailed financial information and updates on operational performance, making it difficult to gauge the company's current state. The focus on platform development and addressing customer needs is positive, but concerns about regulatory hurdles and strategic execution risks introduce uncertainties. The absence of explicit financial metrics or shareholder return plans further limits positive sentiment. Overall, the lack of critical financial details and mixed strategic signals suggest a neutral outlook.
American Well Corporation (AMWL) Q4 2025 Earnings Call Transcript
Unknown2-13
The earnings call reveals significant declines in revenue, subscription, and visit metrics, alongside reduced gross profit and margin pressure. Despite improved operating expenses and EBITDA, the lack of clear guidance on DHA renewal and AI integration impact, coupled with unclear management responses, heightens uncertainty. The Q&A section suggests optimism but lacks concrete data, and the 2026 guidance presents both headwinds and tailwinds. The absence of a market cap limits precise prediction, but overall sentiment leans negative due to financial declines and uncertainty in strategic renewals.
CAVA Group, Inc. (CAVA) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call summary presents a mixed picture: while there are positive elements such as improved subscription revenue and cost reduction initiatives, the revised revenue guidance and negative EBITDA projections temper the outlook. The Q&A section highlights concerns about operational challenges and macroeconomic pressures, which, along with unclear management responses, suggest cautious investor sentiment. The overall sentiment is neutral, as the positive and negative factors seem to balance each other out.
American Well Corporation (AMWL) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call presents a mixed but generally positive outlook. Despite a revenue guidance cut, the company shows strong cost containment and improving margins, with a significant GAAP gross margin increase. The Q&A highlights strategic wins like the Florida Blues plan, divestiture focus, and AI's role in efficiency, all suggesting positive market sentiment. The EBITDA loss improvement and cash position are reassuring, while the lack of detailed guidance on AI's financial impact is a minor concern. Overall, the strategic focus and financial health indicators suggest a positive stock reaction.
AMWL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
